SCHEMBL1879486

SCHEMBL1879486

Cc1cccc2cc(C(C)N3C(=O)c4ccccc4C3=O)c(-c3ccccc3)nc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.52
PIK3CD O00329 1/20 0.42
MAPT P10636 2/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
PDE1A P54750 1/20 0.38
PDE1B Q01064 1/20 0.38
PDE1C Q14123 1/20 0.38
LMNA P02545 1/20 0.37
USP2 O75604 1/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19753813 0.87 PIK3CD (0.39) ATMPIK3CDLMNAUSP2TSHR
SCHEMBL15307163 0.87 PIK3CD (0.39) ATMPIK3CDLMNAUSP2TSHR
SCHEMBL15336917 0.87 PIK3CD (0.39) ATMPIK3CDLMNAUSP2TSHR
SCHEMBL17657972 0.84 ATM (0.35) ATMPIK3CDMAPTPDE1APDE1B
SCHEMBL10285463 0.84 ATM (0.48) ATMPIK3CDMAPTMAPK1RAB9A
SCHEMBL1883714 0.77 ATM (0.48) ATMPIK3CDMAPTMAPK1RAB9A
SCHEMBL1881106 0.77 ATM (0.48) ATMPIK3CDMAPTMAPK1RAB9A
SCHEMBL1878845 0.77 ATM (0.48) ATMPIK3CDMAPTMAPK1RAB9A
SCHEMBL4181555 0.75 PIK3CD (0.46) PIK3CDLMNAKDM4EGAAALDH1A1
SCHEMBL4181554 0.75 PIK3CD (0.46) PIK3CDLMNAKDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE ATM 545/4885PIK3CD 8/4885MAPT 2318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.